Novo Nordisk Cuts Prices for Popular Weight-Loss Drugs Wegovy and Ozempic
Novo Nordisk, the pharmaceutical company behind Wegovy and Ozempic, has announced a significant reduction in the list prices of these widely-used medications aimed at managing diabetes and promoting weight loss. This decision comes alongside the U.S. Food and Drug Administration (FDA) approving a new, higher-dose version of Wegovy.
On Thursday, the FDA granted approval for a 7.2 mg injection of Wegovy, designed specifically for weight loss and long-term maintenance for adults. This new dosage is three times higher than the previous maximum dose of 2.4 mg.
The FDA’s approval is part of an initiative to accelerate products that address critical health issues in the U.S., emphasizing the organization’s commitment to efficiency. FDA Commissioner Dr. Martin Makary noted that this approval exemplifies how the agency can achieve remarkable results by innovating.
The new Wegovy injection aims to help adults not just lose weight but also maintain that weight loss effectively. The FDA underscored that this higher dose offers patients a more robust option, particularly for those facing obesity or overweight conditions related to other health issues.
Clinical trials indicated that patients using the higher dosage experienced greater average weight loss compared to those on the lower dose. In particular, individuals with obesity and type 2 diabetes showed similar benefits in blood sugar control with both doses.
However, the FDA also highlighted that patients should consult with doctors on the proper use of Wegovy, especially for those with a personal or family history of specific thyroid conditions.
Dr. Jamey Millar from Novo Nordisk expressed excitement about the new option for adults struggling with obesity, stating that Wegovy has proven effective in reducing risks of heart attack and stroke for patients with heart disease.
Experts have noted that while the higher-dose Wegovy represents a significant step forward, it should mainly be used for managing obesity. Some specialists believe this new approach offers a viable option for patients who may have hit a plateau with lower doses or who have higher baseline body weights.
In summary, the combination of reduced prices and higher dosing options marks a new chapter for Wegovy and Ozempic, potentially enhancing accessibility for many patients and aligning with evolving healthcare needs.
